J

Jazz Pharmaceuticals plc
D

JAZZ

126.690
USD
1.52
(1.21%)
Market Closed
Volume
24,957
EPS
20
Div Yield
-
P/E
18
Market Cap
7,658,992,260
OverviewSignalsIdeasNews
Related Instruments
    AMGN
    AMGN
    -12.22
    (-4.13%)
    294.4 USD
    AZN
    AZN
    -1.830
    (-2.81%)
    65.635 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    LLY
    LLY
    -40.34
    (-5.13%)
    748 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.16 USD
    NVS
    NVS
    -0.350
    (-0.34%)
    104.29 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.63 USD
    SNY
    SNY
    0.160
    (0.33%)
    48.275 USD
    More
News

Title: Jazz Pharmaceuticals plc

Sector: Healthcare
Industry: Biotechnology
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.